Eisai

Biogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – BIIB

Retrieved on: 
fredag, maj 31, 2024
BIIB, COST, Risk, CLASS, Telephone, EPS, LLP, Court, Eisai, FY, NEXT, Cryptocurrency

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 13, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    BIIB investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
torsdag, maj 30, 2024
BIIB, Biogen, Risk, Person, EPS, Court, Eisai, FY, Complaint, Security (finance)

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIIB .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIIB .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.

Retrieved on: 
fredag, maj 31, 2024
Class Action Lawsuit, Professional Services, Legal, BIIB, Medicare, Hope, News, Risk, HERE, FDA, EPS, Acquisition, LLP, Eisai, FY, District court, DOJ, Lead, Security (finance)

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) ( NASDAQ: BIIB ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) ( NASDAQ: BIIB ).
  • The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • If you suffered Biogen losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/biogen-inc-1?utm_source=PR&utm_medium=lin...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Biogen investors who have suffered significant losses to contact the firm directly to acquire more information.

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
torsdag, maj 30, 2024
Class Action Lawsuit, Professional Services, Legal, BIIB, Biogen, Risk, Person, EPS, Court, Eisai, FY, Complaint, Security (finance)

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIIB .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea

Retrieved on: 
tisdag, maj 28, 2024
Patient, Ministry, KRW, Nursing, Diagnosis, MFDS, Alzheimer's disease, Neuron, Cell, Dementia, Eisai, Brain, MCI, Pharmaceutical industry

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.

Key Points: 
  • LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • South Korea is the fourth country to grant approval, following approvals in the U.S., Japan, and China.
  • In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities.
  • Eisai is committed to working together with healthcare professionals and other stakeholders to realize the early diagnosis and treatment of AD.

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan

Retrieved on: 
onsdag, maj 22, 2024
Patient, MTX, Rheumatoid arthritis, Skin, Safety, NHI, Marketing, Gesellschaft mit beschränkter Haftung, National health insurance, Arthritis, Eisai, Pharmaceutical industry

TOKYO, May 22, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan.

Key Points: 
  • TOKYO, May 22, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan.
  • Metoject Subcutaneous Injection Pen will be the first self-administrable MTX subcutaneous injection pen-type autoinjector for rheumatoid arthritis in Japan and was developed to reduce the burden on patients and improve safety during self- injection.
  • "By adding Metoject Subcutaneous Injection Pen to Eisai's product lineup, we are making further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients."
  • Product name: Metoject Subcutaneous Injection 7.5mg pen 0.15mL, 10mg pen 0.20mL, 12.5mg pen 0.25mL and 15mg pen 0.30mL
    Generic name: Methotrexate Indication for use: Rheumatoid arthritis Dosage and administration:
    The usual adult dose of methotrexate is 7.5mg injected subcutaneously once a week.

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
onsdag, maj 29, 2024
Human services, Partnership, BIIB, Patient, Medicare, Friedreich's ataxia, News, Risk, Food, Medicaid, FDA, Telephone, Person, Conference, Publication, Multiple sclerosis, Traction, EPS, Alzheimer's disease, Defendant, Acquisition, United States congressional committee, GAAP, Court, P.C, Eisai, FY, Physician, District court, DOJ, Complaint, Pharmaceutical industry

Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
  • Biogen's sales of its MS-related products have historically accounted for the majority of the Company's product revenues.
  • Accordingly, because AD-related treatments represented a lucrative market for Biogen, the Company's AD-related products were particularly important to Defendants and investors throughout the Class Period.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

Retrieved on: 
tisdag, maj 28, 2024
Partnership, BIIB, Medicare, News, Risk, Medicaid, Biogen, FDA, Prior, Ext, Defendant, United States congressional committee, LLP, Court, FY, District court, Complaint, Publication, Conference, Multiple sclerosis, Traction, Action Replay, Physician, Human services, Food, EPS, Pomerantz, Patient, Person, Acquisition, Eisai, Pharmaceutical industry

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
lördag, maj 25, 2024
Human services, Partnership, BIIB, Patient, Medicare, Friedreich's ataxia, News, Risk, Food, Medicaid, FDA, Telephone, Person, Conference, Publication, Multiple sclerosis, Traction, EPS, Alzheimer's disease, Defendant, Acquisition, United States congressional committee, GAAP, Court, P.C, Eisai, FY, Physician, District court, DOJ, Complaint, Pharmaceutical industry

Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
  • Biogen's sales of its MS-related products have historically accounted for the majority of the Company's product revenues.
  • Accordingly, because AD-related treatments represented a lucrative market for Biogen, the Company's AD-related products were particularly important to Defendants and investors throughout the Class Period.

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
torsdag, maj 23, 2024
BIIB, Biogen, Risk, Person, EPS, Court, Eisai, FY, Complaint, Security (finance)

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIIB .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIIB .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.